Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VetoquinolXPAR:VETO -1.78%94 Days Payable is 952.03 as of Dec. 2025, which is 890% above its 10-year median of 96.18. GuruFocus rates XPAR:VETO with a GF Score™ of 94/100 and a GF Value™ of €85.39 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 927 Drug Manufacturers companies, Vetoquinol ranks better than 81.55% on this metric.
Vetoquinol's average Accounts Payable for the
six
months ended in Dec. 2025 was €80.4 Mil. Vetoquinol's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €15.4 Mil.
Hence, Vetoquinol's Days Payable for the
six
months ended in Dec. 2025 was 952.03.
The historical rank and industry rank for Vetoquinol's Days Payable or its related term are showing as below:
XPAR:VETO'
s Days Payable Range Over the Past 10 Years
Min: 80.06 Med: 96.18 Max: 183.31
Current: 183.31
During the past 13 years, Vetoquinol's highest Days Payable was 183.31. The lowest was 80.06. And the median was 96.18.
XPAR:VETO's Days Payable is ranked better than 81.55% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.28
vs XPAR:VETO: 183.31
Vetoquinol's Days Payable
increased
from Dec. 2024 (781.22) to Dec. 2025 (952.03).
It may suggest that Vetoquinoldelayed paying its suppliers.
The historical data trend for Vetoquinol's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:VETO vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vetoquinol's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vetoquinol Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vetoquinol's Days Payable distribution charts can be found below:
* The bar in red indicates where Vetoquinol's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vetoquinol's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vetoquinol (XPAR:VETO) has a Days Payable of 952.03 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vetoquinol and its competitors. This is 890% above median its historical median of 96.18. Over the past decade, Vetoquinol's Days Payable has ranged from 80.06 to 183.31. According to the industry distribution chart, Vetoquinol ranks #171 out of 927 companies in the Drug Manufacturers industry, placing it in the top 18.4%.
Is Vetoquinol's Days Payable too high?
Vetoquinol's current Days Payable of 952.03 is 890% above median its 10-year median of 96.18. Over the past 10 years, this metric has ranged from a low of 80.06 to a high of 183.31. The Drug Manufacturers industry median Days Payable is 90.28. Vetoquinol's value of 952.03 is 954.5% above this industry median. Based on the distribution chart, Vetoquinol ranks #171 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vetoquinol has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vetoquinol's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vetoquinol ranks #171 out of 927 companies for Days Payable. This places Vetoquinol in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.28. Vetoquinol's value of 952.03 is 954.5% above this benchmark. Historically, Vetoquinol's own Days Payable has ranged from 80.06 to 183.31 over the past decade. While the company's 10-year median is 96.18 vs. the industry median of 90.28, Vetoquinol has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vetoquinol's current Days Payable of 952.03 is 954.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vetoquinol and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vetoquinol's current Days Payable is 952.03, which is 890% above median its own 10-year median of 96.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vetoquinol stock overvalued right now?
Based on GuruFocus' analysis, Vetoquinol (XPAR:VETO) is currently considered Modestly Undervalued. The stock's GF Value™ is €85.39, compared to a current price of €71.70 — trading 16% below its estimated fair value. The current Days Payable is 952.03, which is 890% above median its 10-year median of 96.18 and 954.5% above the Drug Manufacturers industry median of 90.28. Vetoquinol's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vetoquinol (XPAR:VETO), the current Days Payable is 952.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vetoquinol (XPAR:VETO) Overvalued in 2026?
Based on GuruFocus' analysis, Vetoquinol stock appears to be undervalued.
The current stock price of €71.70 is trading 16% below its estimated GF Value™ of €85.39.
GuruFocus considers Vetoquinol to be Modestly Undervalued.
Key valuation signals for XPAR:VETO:
Days Payable: 952.03 (890% above median its 10-year median of 96.18)
GF Value™: €85.39 vs. price of €71.70 (16% below fair value)
Industry Position: 954.5% above the Drug Manufacturers median (#171 of 927)
No single metric tells the full story. See the XPAR:VETO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
94GF Score
Get the complete analysis for XPAR:VETO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:VETO has been successfully added to your 
